Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2

International Journal of Biological Markers

Volumn 14, Issue 3, 1999, Pages 167-171

  Lissoni, P ^a   Bolis, S ^a   Mandala M ^a   Viviani, S ^b   Pogliani, E ^a   Barni, S ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Immunotherapy; Interleukin 2; Malignant lymphomas; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CYTOKINE RELEASE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PROTEIN BLOOD LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032726236     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400308     Document Type: Article

References (18)

1. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
2. Haranaka K, Satomi N. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. Jpn J Exp Med 1981; 51: 191-4.
3. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. J Immunol 1994; 153: 1674-85.
4. Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in metastatic disease. J Biol Regul Homeost Agents 1992; 6: 103-7.
5. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996; 56: 5499-505.
6. Wagner DK, Kiwanuka J, Brenda K, et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987; 5: 1262-74.
7. Macia J, Gomez X, Esquerda A, et al. Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 20: 481-6.
8. Zinzani PL, Baccini C, Zaccaria A, et al. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur J Haematol 1996; 57: 335-40.
9. Tesch H, Feller AC, Jucker M, et al. Activation of cytokines in Hodgkin's disease. Ann Oncol 1992; 3 (Suppl 4): 13-6.
10. Gause A, Jung W, Keymis S, et al. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease. Leuk Lymphoma 1992; 7: 439-47.
11. Warzoka K, Bienvenu J, Ribeiro P, et al. Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998; 77: 2357-62.
12. Whittington R, Faulds D. Interleukin-2. Drugs 1993; 46: 446-514.
13. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992; 3: 475-80.
14. Fefer A. Interleukin-2 in the treatment of hematologic malignancies. Cancer J Sci Am 1997; 3 (Suppl 1): S35-6.
15. Atzpodien J, Kirchner H. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 1990; 68: 1-11.
16. Lissoni P, Barni S, Tancini G, et al. A randomized study with subcutaneous low-dose interleukin-2 alone vs. interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994; 69: 196-9.
17. Gisselbrecht C, Maraninchi D, Pico JM, et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081-5.
18. Fefer A, Robinson N, Benyunes MC, et al. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer J Sci Am 1997; 3 (Suppl 1): S48-53.